natgillin/translations-raw huggingface dataset:
How to store Effentora
Shranjevanje zdravila Effentora
You may drink some water before using Effentora to help moisten your mouth, but you should not drink or eat anything while taking the medicine.
Preden uporabite zdravilo Effentora, lahko spijete nekaj vode, da navlažite svoja usta.
• fatigue
• zardevanje
The concomitant use of alcohol with fentanyl can produce increased depressant effects which may result in a fatal outcome (see section 4.5).
Sočasna uporaba alkohola in fentanila lahko poveča pomirjevalne učinke, kar lahko povzroči smrt
Medicinal product subject to special and restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Povzetek glavnih značilnosti zdravila, poglavje 4.2).
Effentora must not be prescribed in patients with short term pain only 3.
Zdravila Effentora ni dovoljeno predpisati bolnikom z bolečino, ki traja kratek čas
Opioid withdrawal symptoms such as nausea, vomiting, diarrhoea, anxiety, chills, tremor and sweating have been observed with transmucosal fentanyl.
Pri uporabi transmukoznega fentanila so opazili opioidne odtegnitvene sindrome, kot so navzea, bruhanje, driska, ansioznost, mrzlica, tremor in znojenje.
If you notice any of these, contact your doctor.
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom.
The educational material for patients shall consist of the following three items:
prejeli izobraževalni paket z naslednjo vsebino:
• unusually low heart rate, feeling very warm (hot flushes),
• moten ali zameglen vid, rdeče oko • neobičajno počasen srčni utrip, občutek vročine (vročinski oblivi)
It is recommended that increased caution should be exercised in titrating the dose of Effentora in elderly patients.
Pri titriranju odmerka zdravila Effentora pri starejših bolnikih se priporoča pazljivost.
Effentora 400 micrograms buccal tablets EU/1/08/441/005-006
Effentora 400 mikrogramov bukalne tablete EU/1/08/441/005-006
• The tablet should be left between the cheek and gum until dissolved, which usually takes approximately 14 to 25 minutes.
To običajno traja 14 do 25 minut.
The concomitant use of Effentora with strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, and nelfinavir) or moderate CYP3A4 inhibitors (e.g.,
Hkratno jemanje zdravila Effentora z močnimi zaviralci CYP3A4 (npr. ritonavir, ketokonazol,
• constipation, inflammation of the mouth, dry mouth, diarrhoea, heartburn, loss of appetite,
• zaprtost, vnetje ust, suha usta, diareja, zgaga, izguba apetita, bolečina v trebuhu, nelagodje v trebuhu, prebavne motnje, zobobol, ustni oprh
Effentora 200 micrograms buccal tablets EU/1/08/441/003-004
Effentora 200 mikrogramov bukalne tablete EU/1/08/441/003-004
Effentora 800 micrograms buccal tablets Each buccal tablet contains 800 micrograms fentanyl (as citrate).
Effentora 800 mikrogramov bukalne tablete Ena bukalna tableta vsebuje 800 mikrogramov fentanila (v obliki citrata).
Dose readjustment
Ponovna prilagoditev odmerka
Hypotension Hypertension
Žilne bolezni hipotenzija, hipertenzija zardevanje,
• Allergic reactions such as rash, redness, swollen lip and face, hives
• alergijske reakcije kot so izpuščaj, rdečina, otekle ustnice in obraz, koprivnica Neznana: pogostnosti ni mogoče oceniti iz razpoložljivih podatkov
Dose titration
Odmerjanje Titriranje odmerka
Taking the medicine
Pri apliciranju zdravila
Effentora 800 micrograms buccal tablets EU/1/08/441/009-010
Effentora 800 mikrogramov bukalne tablete EU/1/08/441/009-010
Patients should wait at least 4 hours before treating another BTP episode with Effentora during maintenance therapy.
Pred zdravljenjem naslednje epizode PBB z zdravilom Effentora mora bolnik med vzdrževalno terapijo počakati vsaj 4 ure.
Dizziness Headache
bolečino,
Effentora 600 micrograms buccal tablets EU/1/08/441/007-008
Effentora 600 mikrogramov bukalne tablete EU/1/08/441/007-008
• Contact your doctor immediately if you experience a combination of the following symptoms
• Če se pojavi kombinacija spodnjih simptomov, se takoj obrnite na zdravnika
Effentora 100 micrograms buccal tablets EU/1/08/441/001-002
Effentora 100 mikrogramov bukalne tablete EU/1/08/441/001-002
Driving and using machines
(npr. vožnja avtomobila ali upravljanje strojev).
Effentora 200 micrograms buccal tablets Each buccal tablet contains 200 micrograms fentanyl (as citrate).
Effentora 200 mikrogramov bukalne tablete Ena bukalna tableta vsebuje 200 mikrogramov fentanila (v obliki citrata).
Effentora 400 micrograms buccal tablets Each buccal tablet contains 400 micrograms fentanyl (as citrate).
Effentora 400 mikrogramov bukalne tablete Ena bukalna tableta vsebuje 400 mikrogramov fentanila (v obliki citrata).
Depression Anxiety Confusional state
Psihiatrične motnje depresija, tesnoba, stanje zmedenosti,
These might be early symptoms of a serious allergic reaction (anaphylaxis, hypersensitivity; see section 4 under “Serious side effects”)
(anafilaksa, preobčutljivost; glejte poglavje 4 pod »Resni neželeni učinki«).
Effentora 100 micrograms buccal tablets Each buccal tablet contains 100 micrograms fentanyl (as citrate).
Effentora 100 mikrogramov bukalne tablete Ena bukalna tableta vsebuje 100 mikrogramov fentanila (v obliki citrata).
Skin and subcutaneous tissue disorders
Bolezni kože in podkožja pruritus, hiperhidroza,
• EFFENTORA prescribing guide
• Vodnika za predpisovanje zdravila EFFENTORA • Vodnika za orodje za titriranje
Effentora should be placed and retained within the buccal cavity for a period sufficient to allow disintegration of the tablet which usually takes approximately 14-25 minutes.
Zdravilo Effentora se vstavi v ustno votlino, kjer naj ostane dovolj dolgo, da se tableta razkroji.
• Any medicines that might have an effect on the way in which your body breaks down Effentora, such as ritonavir, nelfinavir, amprenavir, and fosamprenavir (medicines that help control HIV infection) or other so-called CYP3A4 inhibitors such as ketoconazole, itraconazole, or fluconazole (used for treatment of fungal infections), troleandomycine, clarithromycine, or erythromycine (medicines for treatment of bacterial infections), aprepitant (used for severe nausea) and diltiazem and verapamil (medicines for treatment of high blood pressure or heart diseases).
itrakonazol, troleandomicin, klaritromicin in nelfinavir) ali zmernimi zaviralci CYP3A4 (npr. amprenavir, aprepitant, diltiazem, eritromicin, flukonazol, fosamprenavir, sok grenivke in verapamil)
• If you suffer from short-term pain other than breakthrough pain
• če imate drugo kratkotrajno bolečino, ki ni prebijajoča bolečina, kot je bolečina zaradi poškodb ali operacije, glavobola ali migrene.
Effentora tablet once exposed to moisture utilises an effervescent reaction to deliver the active substance.
Ko so tablete Effentora izpostavljene vlagi, se razkrojijo in sprostijo učinkovino.
• 800 micrograms fentanyl (as citrate)
• 800 mikrogramov fentanila (v obliki citrata)
Each buccal tablet contains 800 micrograms fentanyl (as citrate)
Ena bukalna tableta vsebuje 800 mikrogramov fentanila (v obliki citrata).
Patients should wait at least 4 hours before treating another BTP episode with Effentora during titration.
Pred zdravljenjem naslednje epizode PBB z zdravilom Effentora mora bolnik med titriranjem počakati vsaj 4 ure.
Effentora 800 micrograms buccal tablets
Effentora 800 mikrogramov bukalne tablete fentanil
• 200 micrograms fentanyl (as citrate)
• 200 mikrogramov fentanila (v obliki citrata)
Effentora 100 micrograms buccal tablets Fentanyl
Effentora 100 mikrogramov bukalne tablete fentanil
Each buccal tablet contains 200 micrograms fentanyl (as citrate)
Ena bukalna tableta vsebuje 200 mikrogramov fentanila (v obliki citrata).
Nausea Vomiting
vročinski valovi
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “8”.
Effentora 800 mikrogramov bukalne tablete Ploska, bela, okrogla prirezana tableta z oznako ‘C' na eni strani in na drugi strani ‘8'.
• 600 micrograms fentanyl (as citrate)
• 600 mikrogramov fentanila (v obliki citrata)
Each buccal tablet contains 600 micrograms fentanyl (as citrate)
Ena bukalna tableta vsebuje 600 mikrogramov fentanila (v obliki citrata).
• 400 micrograms fentanyl (as citrate)
• 400 mikrogramov fentanila (v obliki citrata)
Effentora 200 micrograms buccal tablets Fentanyl
Effentora 200 mikrogramov bukalne tablete fentanil
Each buccal tablet contains 400 micrograms fentanyl (as citrate)
Ena bukalna tableta vsebuje 400 mikrogramov fentanila (v obliki citrata).
Each buccal tablet contains 100 micrograms fentanyl (as citrate)
Ena bukalna tableta vsebuje 100 mikrogramov fentanila (v obliki citrata).
Effentora 600 micrograms buccal tablets
Effentora 600 mikrogramov bukalne tablete fentanil
It is very important that you use Effentora exactly as the doctor tells you The initial dose is 100 micrograms.
Zelo pomembno je, da zdravilo Effentora uporabljate natančno po navodilih zdravnika.
Constipation Stomatitis Dry mouth Diarrhoea Abdominal pain Gastrooesophageal reflux disease Stomach discomfort Dyspepsia Toothache
Bolezni dihal, prsnega koša in mediastinaln ega prostora dispneja, faringolaringal na bolečina respiratorna depresija, sindrom spalne apneje respiratorni arest*
Effentora 400 micrograms buccal tablets
Effentora 400 mikrogramov bukalne tablete fentanil
• 100 micrograms fentanyl (as citrate)
• 100 mikrogramov fentanila (v obliki citrata)
Effentora 600 micrograms buccal tablets Each buccal tablet contains 600 micrograms fentanyl (as citrate).
Effentora 600 mikrogramov bukalne tablete Ena bukalna tableta vsebuje 600 mikrogramov fentanila v obliki citrata).
Application site reactions including bleeding, pain, ulcer, irritation, paraesthesia, anaesthesia, erythema, oedema, swelling and vesicles
razjedo, draženjem, parestezijo, anesezijo, eritemom, edemom, oteklostjo in mehurčki periferni edem, utrujenost, astenija, odtegnitveni sindrom*, mrzlica splošno slabo počutje,
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “1”.
Effentora 100 mikrogramov bukalne tablete Ploska, bela, okrogla prirezana tableta z oznako ‘C' na eni strani in na drugi strani ‘1'.
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “6”.
Effentora 600 mikrogramov bukalne tablete Ploska, bela, okrogla prirezana tableta z oznako ‘C' na eni strani in na drugi strani ‘6'.
Peripheral oedema Fatigue Asthenia Drug withdrawal syndrome* Chills
Infekcijske in parazitske bolezni ustna kandidiaza faringitis oralne pustule
vomiting, diarrhoea, anxiety, chills, tremor, and sweating), shaking, falls, chills
odtegnitveni sindrom, (lahko se kaže s pojavom naslednjim neželenih učinkov: siljenje na bruhanje, bruhanje, driska, tesnoba, mrzlica, tremor in znojenje) tresenje, padci, mrzlice
Chronic obstructive pulmonary disease
Bolezni sečil zastajanje urina
Vertigo Tinnitus Ear discomfort
vključno z motnjami labirinta vrtoglavica, tinitus, nelagodje v ušesu
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “2”.
Effentora 200 mikrogramov bukalne tablete Ploska, bela, okrogla prirezana tableta z oznako ‘C' na eni strani in na drugi strani ‘2'.
If your breakthrough pain is not relieved after 30 minutes, use only 1 more tablet of Effentora during the titration period.
30 minut, tokrat uporabite samo 1 dodatno tableto zdravila Effentora v obdobju titriranja.
Fall
Olupite
Flat-faced, white, round bevelled-edge tablet, embossed on one side with a “C” and on the other side with “4”.
Effentora 400 mikrogramov bukalne tablete Ploska, bela, okrogla prirezana tableta z oznako ‘C' na eni strani in na drugi strani ‘4'.
This medicine must be kept out of the sight and reach of children.
To zdravilo shranjujte nedosegljivo otrokom!
Hypersensitivity reactions have been reported in post-marketing experience, including rash, erythema, lip and face swelling, and urticaria (see section 4.4).
eritemom, otekanjem ustnic in obraza in urtikarijo (glejte poglavje 4.4).
Platelet count decreased Heart rate increased Haematocrit decreased Haemoglobin decreased
Preiskave zmanjšanje telesne mase zmanjšanje števila trombocitov, hitro utripanje srca, zmanjšanje hematokrita, zmanjšanje hemoglobina
• Titration guide tool Key elements to be included in the educational material for healthcare professionals: - Prescription of EFFENTORA only by physicians experienced in the management of opioid therapy in cancer patients - Prescription of EFFENTORA only to critically selected patients with close following on
- Zdravilo EFFENTORA lahko predpisujejo samo zdravniki z izkušnjami v vodenju opioidnega zdravljenja pri bolnikih z rakom
Patients should not consume any food and drink when a tablet is in the buccal cavity.
S tableto v ustni votlini bolniki ne smejo niti jesti niti piti.
Mouth ulceration Oral hypoaesthesia Oral discomfort Oral mucosal discolouration Oral soft tissue disorder Glossodynia Tongue blistering Gingival pain Tongue ulceration Tongue disorder Oesophagitis Chapped lips Tooth disorder
bolečine v trebuhu, gastroezofagealna refluksna bolezen, nelagodje v trebuhu, dispepsija, zobobol ileus, razjede v ustih, oralna hipoestezija, nelagodje v ustih, obarvanje ustne sluznice, bolezni mehkih ustnih tkiv,, glosodinija,
Strength Pharmaceutical Form
Izmišljeno ime jakost farmacevtska oblika pot uporabe ovojnina
London, 24 May 2007 Doc.
London, 24. maj 2007 Sklic na dok.
The Committee was also concerned over the safety of the medicine and the consistency of the medicine between batches.
Odbor je imel tudi zadržke v zvezi z varnostjo zdravila in konsistentnostjo zdravila med serijami.
The main measure of effectiveness was the improvement in vision three months after the injection, assessed using a standard letter chart.
Glavno merilo učinkovitosti je bilo izboljšanje vida tri mesece po injekciji, ki je bilo ocenjeno s standardnim listom s črkovnimi znaki.
International non-proprietary name (INN): hyaluronidase (ovine)
Mednarodno nelastniško ime (INN): hialuronidaza (ovčja)
Ref. EMEA/195786/2007
EMEA/253858/2007
The effects of Vitragan were first tested in experimental models before being studied in humans.
Učinki zdravila Vitragan so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
QUESTIONS AND ANSWERS ON THE WITHDRAWAL OF THE MARKETING APPLICATION for VITRAGAN
VPRAŠANJA IN ODGOVORI GLEDE UMIKA VLOGE ZA DOVOLJENJE ZA PROMET za zdravilo VITRAGAN
On 25 April 2007, ISTA Pharma Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Vitragan, for the treatment of vitreous haemorrhage.
Podjetje ISTA Pharma Limited je dne 25. aprila 2007 obvestilo Odbor za zdravila za uporabo v humani medicini (CHMP), da se je odločilo umakniti vlogo za dovoljenje za promet z zdravilom Vitragan, namenjenim za zdravljenje krvavitev v steklovino.
It was to be made up into a solution for injection into the eye.
Namenjen je za pripravo raztopine za injiciranje v oko.
This was intended to improve vision and to help doctors in their diagnosis of underlying problems in the retina (the light-sensitive surface at the back of the eye).
Namenjeno bi naj bilo za izboljšanje vida in kot pomoč zdravnikom pri diagnosticiranju osnovnih težav v mrežnici (na svetlobo občutljivi površini na zadnji strani očesa).
The company also presented the results of two main studies involving 1,306 patients with vitreous haemorrhage, where the effects of a single injection of Vitragan were compared with those of placebo (a dummy treatment).
Podjetje je predstavilo tudi rezultate dveh glavnih študij s 1306 bolniki s krvavitvami v steklovino, v katerih so učinke posamične injekcije zdravila Vitragan primerjali z učinki placeba.
When the acid is broken down, the vitreous humour turns from a jelly into a liquid, allowing cells to move more freely through the vitreous humour.
Ko se kislina razgrajuje, se steklovina spreminja iz želatine v tekočino, kar omogoča celicam prosto gibanje skozi steklovino.
What are the consequences of the withdrawal for patients undergoing clinical trials or compassionate use programmes with Vitragan?
Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih/programih sočutne uporabe zdravila Vitragan?
What is Vitragan?
Kaj je zdravilo Vitragan?
This was expected to allow phagocytes (specialised ‘scavenger' cells of the immune system) to clear away any blood clots from the vitreous humour.
To naj bi omogočilo fagocitom (specializirane „čistilne“ celice imunskega sistema) odstranjevanje krvnih strdkov iz steklovine.
The active substance in Vitragan, hyaluronidase (ovine), is an enzyme extracted from sheep.
Zdravilna učinkovina v zdravilu Vitragan, hialuronidaza (ovčja), je encim, pridobljen iz ovc.
Based on the review of the data and the company's response to the CHMP list of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Vitragan could not have been approved for the treatment of vitreous haemorrhage.
Na podlagi pregleda podatkov in odgovorov podjetja na seznam vprašanj, ki jih je zastavil CHMP, je imel Odbor v času umika vloge zadržke in bil začasnega mnenja, da za zdravilo Vitragan ni mogoče odobriti dovoljenja za zdravljenje krvavitev v steklovino.
Vitragan was expected to be used to treat vitreous haemorrhage (bleeding into the vitreous humour, the jelly-like fluid in the central chamber of the eye) in adults.
Zdravilo Vitragan naj bi se uporabljalo za zdravljenje krvavitev v steklovino (želatini podobno tekočino v osrednji očesni komori) pri odraslih.
The application was at day 180 when the company withdrew.
Ko jo je podjetje umaknilo, je bila vloga v postopku 180. dan.
Vitragan is a powder containing the active substance hyaluronidase (ovine).
Zdravilo Vitragan je prašek, ki vsebuje zdravilno učinkovino hialuronidazo (ovčjo).
The CHMP had concerns over the benefits of Vitragan, since the main studies had not shown convincingly that it was more effective than available options for managing vitreous haemorrhage.
CHMP je imel zadržke glede koristi zdravila Vitragan, saj glavni študiji nista prepričljivo pokazali, da bi bilo zdravilo pri zdravljenju krvavitev v steklovino učinkovitejše od razpoložljivih možnosti.
Therefore, at the time of the withdrawal, the CHMP's view was that a benefit of Vitragan had not been sufficiently demonstrated and any benefits did not outweigh the identified risks.
Zato je bil v času umika CHMP mnenja, da koristi zdravila Vitragan niso zadostno dokazane in da niso večje od znanih tveganj.
What was Vitragan expected to be used for?
Za kaj naj bi se zdravilo Vitragan uporabljalo?
The company informed the CHMP that there are currently no clinical trials or compassionate use programmes with Vitragan.
Podjetje je CHMP obvestilo, da klinična preizkušanja ali programi sočasne uporabe zdravila Vitragan trenutno ne potekajo.
How is Vitragan expected to work?
Kako naj bi zdravilo Vitragan delovalo?
It is expected to work by breaking down a molecule in the vitreous humour called hyaluronic acid.
Ta encim naj bi razgrajeval molekule v steklovini, imenovane hialuronska kislina.
MA (EU) number (Invented) name Strength Pharmaceutical
Številka (EU) dovoljenja za promet
Long-term extension in Study 1 and Study 2
Dolgoročno podaljšanje v Študiji 1 in Študiji 2
Day 5, Day 14 and Day 28
5. dan, 14. dan in 28. dan
Date of latest renewal: 18 February 2016
Datum zadnjega podaljšanja: 18. februar 2016
Polyomavirus 4.8
Poliomavirus 4,8
No pattern was identified in the causes of death.
Pri ugotavljanju vzrokov smrti niso ugotovili nobenih skupnih vzorcev.
(See section 2)
(Glejte poglavje 2)
Study 2: extended criteria donors
Študija 2: darovalci po razširjenih kriterijih
Keep this Alert Card with you at all times.
To opozorilno kartico imejte vedno pri sebi.
The safety and efficacy of belatacept in children and adolescents 0 to 18 years of age have not yet been established.
Varnost in učinkovitost belatacepta pri otrocih in mladostnikih, starih od 0 do 18 let, še nista bili dokazani.
Unopened vials 3 years
Zaprte viale 3 leta
The most common CNS infection was cryptococcal meningitis.
Najpogostejša okužba CŽS je bil kriptokokni meningitis.
Immunosuppressant therapy may affect response to vaccination.
Imunosupresivno zdravljenje lahko vpliva na odziv na cepljenje.
Plasmapheresis may accelerate removal of belatacept.
Plazmafereza lahko pospeši odstranitev belatacepta.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
Obvestite zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katero koli drugo zdravilo.
Up to Year 3*,**
do 1. leta do 3. leta*,**
** Includes all events reported over a median of 3.3 years in the Phase 3 studies, and a median of approximately 7 years in the Phase 2 study.
** Mediani čas pojavnosti vseh sporočenih primerov v študijah 3. faze je 3,3 leta, v študiji 2. faze pa približno 7 let.
Belatacept should not be used in pregnant women unless clearly necessary.
Belatacepta se ne sme uporabljati pri nosečnicah, razen če je nujno potrebno.
* See section “Description of selected adverse reactions”.
* Glejte poglavje “Opis izbranih neželenih učinkov”.
The clinical relevance of such antibodies is unclear.
Klinični pomen teh protiteles ni pojasnjen.
For a list of symptoms please see section 4, “Possible side effects”.
Za seznam simptomov glejte poglavje 4 “Možni neželeni učinki”.
Day of transplantation, prior to implantation (Day 1)
Dan presaditve, pred vsaditvijo (1. dan)
The effects of NULOJIX in pregnant women are not known.
Učinki zdravila NULOJIX pri nosečnicah niso znani.
Direct the stream of fluid to the glass wall of the vial and not into the powder.
Curek tekočine usmerite v stekleno steno viale in ne neposredno v prašek.
These are medicines that reduce the activity of the immune system, the body's natural defences.
Ta zdravila zmanjšujejo aktivnost imunskega sistema, ki je naravni obrambni mehanizem telesa.
There are no adequate data from use of belatacept in pregnant women.
Ni zadostnih podatkov o uporabi belatacepta pri nosečnicah.
Studies in adult mice and monkeys have not demonstrated similar findings.
Pri študijah pri odraslih miših in opicah o takih ugotovitvah niso poročali.
The accumulation index for belatacept at steady state is 1.1.
Indeks akumulacije belatacepta v stanju dinamičnega ravnovesja je 1,1.
Start (Day of Transplant):_______________ Most recent: _________________________ Next treatment date:____________________ Patient's Name:_______________________ Doctor's Name:_______________________ Doctor's Phone:_______________________ If NULOJIX is stopped, keep this card with you for an additional 3 months.
Prvi odmerek (dan presaditve):____________ Zadnji odmerek: _________________________ Datum naslednjega odmerka:_____________ Ime in priimek bolnika:__________________ Ime in priimek zdravnika:_________________ Telefonska številka zdravnika:_____________ To opozorilno kartico imejte pri sebi še vsaj 3 mesece po prekinitvi zdravljenja z zdravilom NULOJIX.
Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving or operating machines.
Bolnikom je treba naročiti, da se morajo v primeru pojava teh simptomov izogibati potencialno nevarnim opravilom, kot so vožnja ali upravljanje s stroji.
This medicine will be stored in the healthcare facility where it is administered.
Zdravilo bo shranjeno v zdravstveni ustanovi, kjer vam ga bodo tudi aplicirali.
Common depression
Pogosti depresija
In general, antibody titers were low, not usually persistent, and often became undetectable with continued treatment.
Titri protiteles so bili na splošno nizki, običajno niso bili persistentni, pri nadaljevanju zdravljenja pa so pogosto postali nedokazljivi.
The frequency categories are defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100).
Kategorije pogostnosti so opredeljene v skladu z naslednjim dogovorom: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100).